Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis

Sokol, Harry; Cosnes, Jacques; Chazouilleres, Olivier; Beaugerie, Laurent; Tiret, Emmanuel; Poupon, Raoul; Seksik, Philippe; Ukleja, Andrew
June 2008
World Journal of Gastroenterology;6/14/2008, Vol. 14 Issue 22, p3497
Academic Journal
AIM: To investigate the phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD). METHODS: Data from 75 PSC-IBD patients evaluated in our tertiary center between 1963 and 2006 were collected and compared to 150 IBD patients without PSC, matched for sex, birth date, IBD diagnosis date and initial disease location regarding ileal, different colonic segments, and rectum, respectively. RESULTS: While PSC-IBD patients received more 5-aminosalicylates (8.7 years/patient vs 2.9 years/patient, P < 0.001), they required less immuno-suppressors (24% vs 46% at 10 years; P < 0.001) and less intestinal resection (10% vs 44% at 10 years, P < 0.001). The 25-year cumulative rate of colectomy was 25.1% in PSC-IBD and 37.3% in controls (P = 0.004). The 25-year cumulative rate of colorectal cancer was 23.4% in PSC-IBD vs 0% in controls (P = 0.002). PSC was the only independent risk factor for the development of colorectal cancer (OR = 10.8; 95%CI, 3.7-31.3). Overall survival rate without liver transplantation was reduced in PSC-IBD patients (67% vs 91% in controls at 25 years, P = 0.001). CONCLUSION: This study confirms that patients with PSC-IBD have a particular disease phenotype independent of the initial disease location. Although their disease is less active and they use more 5-aminosalicylates, they present a higher risk of colorectal cancer.


Related Articles

  • Immune responses triggering colitis and colitis-associated carcinoma. Kesselring, Rebecca; Fichtner-Feigl, Stefan // Langenbeck's Archives of Surgery;Apr2012, Vol. 397 Issue 4, p527 

    Inflammatory bowel diseases compromise of two forms of chronic intestinal inflammatory disorders: Crohn's disease and ulcerative colitis. Both forms of inflammatory bowel disease result from inappropriate inflammatory responses to the intestinal microbiota, but have different underlying immune...

  • The "Natural History" of Inflammatory Bowel Disease and Therapeutic Decisions. Janowitz, Henry D. // American Journal of Gastroenterology;Jun1987, Vol. 82 Issue 6, p498 

    Examines the effectiveness of therapeutics in treating inflammatory bowel disease. Effect of cortisone on ulcerative colitis according to a 1955 study by Truelove and Witts; Maintenance therapy in Crohn's disease; Impact of colectomy on ulcerative colitis.

  • The management of dysplasia associated with ulcerative colitis: colectomy versus continued surveillance. Friedlich, Martin S.; Guindi, Maha; Stern, Hartley S. // Canadian Journal of Surgery;Jun2004, Vol. 47 Issue 3, p212 

    The article focuses on the management of dysplasia associated with ulcerative colitis (UC). Colectomy versus continued surveillance in patients with longstanding UC is a challenging decision. Several factors must be considered. Often such patients have quiescent disease, making the prospect of...

  • Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer. Atreya, R.; Neurath, M. F. // Current Drug Targets;May2008, Vol. 9 Issue 5, p369 

    Although the precise etiology of inflammatory bowel diseases (IBD) still remains unclear, considerable progress has been made in the identification of novel signal transduction pathways that elucidate the immunopathogenesis involved in the perpetuation of the inflammatory process. As both...

  • The lL-8 and IL-13 Gene Polymorphisms in Inflammatory Bowel Disease and Colorectal Cancer. Walczak, Anna; Przybylowska, Karolina; Dziki, Lukasz; Sygut, Andrzej; Chojnacki, Cezary; Chojnacki, Jan; Dziki, Adam; Majsterek, Ireneusz // DNA & Cell Biology;Aug2012, Vol. 31 Issue 8, p1431 

    Inflammatory bowel diseases (IBD) and colorectal cancer (CRC) are disorders that originate from immune disturbances. In our study, we evaluated the association between the −251 T/A interleukin ( IL) -8 and the −1112 C/T IL-13 polymorphisms, the risk of IBD, and CRC development....

  • Role of Cholinergic Receptors in Colorectal Cancer: Potential Therapeutic Implications of Vagus Nerve Stimulation? Pelissier-Rota, Marjolaine; Lainé, Michèle; Ducarouge, Benjamin; Bonaz, Bruno; Jacquier-Sarlin, Muriel // Journal of Cancer Therapy;Aug2013, Vol. 4 Issue 6, p1116 

    Inflammatory Bowel Disease (IBD) patients, such as Crohn's disease or ulcerative colitis suffer from chronic and relapsing intestinal inflammation that favours the development of colitis associated cancer (CAC). This inflammation is initiated by aberrant activations of the innate immune...

  • An updated approach to dysplasia in IBD. Rubin, David T. // Journal of Gastrointestinal Surgery;Dec2008, Vol. 12 Issue 12, p2153 

    Introduction: Long-standing inflammation of the colorectum in ulcerative colitis (UC) and Crohn's disease (CD) has been associated with an increased risk of subsequent dysplasia and colorectal cancer. Historically, it was described that the neoplastic transformation in these...

  • Current concept of pathophysiological understanding and natural course of ulcerative colitis. Holtmann, Martin; Galle, Peter // Langenbeck's Archives of Surgery;Oct2004, Vol. 389 Issue 5, p341 

    Introduction: According to the current paradigm both ulcerative colitis (UC) and Crohn's disease (CD) result from a complex interplay of genetic susceptibility factors, environmental factors, alterations of the physiological intestinal flora and a defective regulation of the intestinal immune...

  • Colorectal cancer and dysplasia in inflammatory bowel disease. Zisman, Timothy L.; Rubin, David T.; Marshall, John K. // World Journal of Gastroenterology;5/7/2008, Vol. 14 Issue 17, p2662 

    Both ulcerative colitis and Crohn's disease carry an increased risk of developing colorectal cancer. Established risk factors for cancer among patients with inflammatory bowel disease (IBD) include the younger age at diagnosis, greater extent and duration of disease, increased severity of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics